Dorsal Column Stimulation Characterization via eECAP Signals
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing medical electrical stimulation devices struggle to objectively optimize electrical stimulation parameters for effective therapy, relying on patient feedback which can be inconsistent and subjective.
Innovation Solution
The use of electrically evoked compound action potential (eECAP) signals to characterize nerve propagation and excitability changes, allowing for the adjustment and optimization of electrical stimulation parameters in a more objective manner.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If patient feedback is used to optimize stimulation parameters, then therapeutic efficacy can be improved, but subjectivity and inconsistency increase
Solution Approach 1:
The patent replaces the subjective patient feedback mechanism with an objective physiological signal detection system. Specifically, it uses eECAP (electrically evoked compound action potential) signals to objectively measure nerve fiber activation and replace the manual, subjective parameter adjustment process with automated, physiology-based optimization, thereby eliminating subjectivity while maintaining therapeutic efficacy.
Solution Approach 2:
The patent implements a closed-loop feedback system where eECAP signals are continuously monitored and used to automatically adjust stimulation parameters. The system measures the physiological response (eECAP) in real-time and feeds this information back to optimize stimulation delivery, creating an automated optimization loop that replaces subjective patient reporting with objective physiological feedback.
2Use of energy by moving object
If electrical stimulation parameters are optimized using eECAP signals, then energy consumption is reduced, but measurement and detection complexity increases
Solution Approach 1:
The patent makes the stimulation electrodes multi-functional by enabling them to both deliver electrical stimulation and detect eECAP signals. This dual functionality eliminates the need for separate sensing hardware, reducing overall system complexity while enabling objective measurement of nerve activation to optimize energy-efficient stimulation delivery.
Solution Approach 2:
The system uses the same electrode infrastructure to both stimulate and sense physiological responses. The electrodes serve themselves by detecting eECAP signals generated in response to their own stimulation, eliminating the need for external or separate measurement systems and reducing overall detection complexity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach enables more targeted and efficient electrical stimulation therapy, reducing energy consumption and improving therapeutic efficacy by allowing for closed-loop stimulation control.
Implementation Method 1
delivering, by a stimulation electrode, electrical stimulation as a candidate therapy to a patient according to a set of candidate therapy parameters, the stimulation electrode located in proximity to the dorsal column of a patient
Implementation Method 2
sensing, by a sensing electrode, an electrically evoked compound action potential (eECAP) signal in response to the delivery of the electrical stimulation
Data Source
AI summary
This disclosure relates to methods, devices, and systems for delivering and adjusting stimulation therapy. In one example, a method comprising delivering, by a stimulation electrode, electrical stimulation as a candidate therapy to a patient according to a set of candidate therapy parameters, the stimulation electrode located in proximity to the dorsal column of a patient; sensing, by a sensing electrode, an electrically evoked compound action potential (eECAP) signal in response to the delivery of the electrical stimulation; and classifying, by a processor, the sensed eECAP signal generated in response to the application of the candidate therapy relative to an eECAP baseline is disclosed.


